Allen, JA
2182  results:
Search for persons X
?
1

D.1 Efficacy, safety, and tolerability of subcutaneous efga..:

Siddiqi, Z ; Allen, JA ; Basta, I...
Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.  51 (2024)  s1 - p. S8-S9 , 2024
 
?
2

U.S. Energy Sector Cybersecurity: Hands-off Approach or Eff..:

Ballou, TM ; Allen, JA ; Francis, KK
Journal of Information Warfare.  15 (2016)  1 - p. 44-59 , 2016
 
?
4

Perceived feasibility, facilitators and barriers to incorpo..:

Green, K ; Micocci, M ; Hicks, T...
https://eprints.whiterose.ac.uk/193406/1/e064038.full.pdf.  , 2022
 
?
5

Patient Preferences for Subcutaneous versus Intravenous Adm..:

Overton PM ; Shalet N ; Somers F.
https://www.dovepress.com/patient-preferences-for-subcutaneous-versus-intravenous-administration-peer-reviewed-fulltext-article-PPA.  , 2021
 
?
6

Individualized immunoglobulin therapy in chronic immune-med..:

Allen, JA ; Berger, M ; Querol, L..
Allen , JA , Berger , M , Querol , L , Kuitwaard , K & Hadden , RD 2018 , ' Individualized immunoglobulin therapy in chronic immune-mediated peripheral neuropathies ' , Journal of the Peripheral Nervous System , vol. 23 , no. 2 , pp. 78-87 . https://doi.org/10.1111/jns.12262.  , 2018
 
?
7

Comparing Social Science and Computer Science Workflow Proc..:

Allen, JA ; Fisher, C ; Chetouani, M...
https://discovery.ucl.ac.uk/id/eprint/10026187/1/Fisher_Article%204_Manuscript%206.16.17.pdf.  , 2017
 
?
 
?
11

Preclinical predictors that the orthosteric mGlu2/3 recepto..:

Witkin, JM ; Monn, JA ; Li, J...
Pharmacology Biochemistry and Behavior.  155 (2017)  - p. 43-55 , 2017
 
1-15